BUZZ-Arrowhead rises as it begins trial of high-cholesterol disorder drug** Shares of Arrowhead Pharmaceuticals rise 2% to $67.95
** California-based drugmaker says it has begun testing its experimental drug ARO-DIMER-PA for mixed hyperlipidemia, a disorder marked by high levels of cholesterol and blood fat
** The drug is designed to silence two genes at once to lower LDL, or "bad" cholesterol, and triglycerides – both linked to heart disease, per co
** Co says the early-stage study will enroll up to 78 adults to assess safety and efficacy
** In earlier animal studies, the drug sharply reduced cholesterol and triglycerides, co say
** Shares up ~253% in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.